It is essential to manage hypertension in cancer patients because uncontrolled high blood pressure can increase the risk of cardiovascular complications and negatively impact overall health. We searched PubMed, Web of Science, EBSCO, Scopus, Google Scholar, Directory of Open Access Journals (DOAJ), and Embase, using keywords including; hypertension, onco-hypertension, and Neoplasms; and found that several factors can contribute to the development of onco-hypertension, including certain types of cancer, chemotherapy drugs, targeted therapies, and hormonal treatments. Favorable cooperation of multi-specialists in this disease treatment can lead to better and more optimal treatment management for these patients.
控制癌症患者的高血压至关重要，因为不受控制的高血压会增加心血管并发症的风险，并对整体健康产生负面影响。我们检索了PubMed、Web of Science、EBSCO、Scopus、Google Scholar、DOAJ和Embase，关键词包括;高血压、肿瘤合并高血压和肿瘤;他们发现，有几个因素会导致肿瘤高血压的发展，包括某些类型的癌症、化疗药物、靶向治疗和激素治疗。多专科医师在本病治疗上的良好合作，可以为这些患者带来更好、更优化的治疗管理。
{"title":"Onco-hypertension; a collaboration among oncologists, nephrologists and cardiologists","authors":"Sara Dehghan","doi":"10.34172/jre.2023.25098","DOIUrl":"https://doi.org/10.34172/jre.2023.25098","url":null,"abstract":"It is essential to manage hypertension in cancer patients because uncontrolled high blood pressure can increase the risk of cardiovascular complications and negatively impact overall health. We searched PubMed, Web of Science, EBSCO, Scopus, Google Scholar, Directory of Open Access Journals (DOAJ), and Embase, using keywords including; hypertension, onco-hypertension, and Neoplasms; and found that several factors can contribute to the development of onco-hypertension, including certain types of cancer, chemotherapy drugs, targeted therapies, and hormonal treatments. Favorable cooperation of multi-specialists in this disease treatment can lead to better and more optimal treatment management for these patients.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89455713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rokhsare Zareie, Mahsa Asadollahi Hamedani, Reyhaneh Sadeghian, Y. Khanchemehr, M. Belali Kharaji, E. Zaremoghadam, Negar Shahkarami, Atena Samareh Fekri
Biomarkers are molecules that can be measured in the body and can reflect disease activity or progression. They can be used to diagnose and monitor disease, predict treatment response, and identify potential therapeutic targets. Several types of biomarkers have been studied in the context of IgA nephropathy, including protein, gene expression, epigenetic, and microRNA biomarkers. Biomarkers have the potential to improve the accuracy and specificity of the diagnosis of IgA nephropathy and predict the disease progression and response to treatment. However, further studies are needed to validate their diagnostic value in larger cohorts of patients and to integrate them into clinical practice. The development of multi-omics approaches that combine different types of biomarkers may provide a more comprehensive understanding of the disease pathogenesis and potential treatments.
{"title":"Biomarkers in IgA nephropathy; an update to recent data","authors":"Rokhsare Zareie, Mahsa Asadollahi Hamedani, Reyhaneh Sadeghian, Y. Khanchemehr, M. Belali Kharaji, E. Zaremoghadam, Negar Shahkarami, Atena Samareh Fekri","doi":"10.34172/jre.2023.25120","DOIUrl":"https://doi.org/10.34172/jre.2023.25120","url":null,"abstract":"Biomarkers are molecules that can be measured in the body and can reflect disease activity or progression. They can be used to diagnose and monitor disease, predict treatment response, and identify potential therapeutic targets. Several types of biomarkers have been studied in the context of IgA nephropathy, including protein, gene expression, epigenetic, and microRNA biomarkers. Biomarkers have the potential to improve the accuracy and specificity of the diagnosis of IgA nephropathy and predict the disease progression and response to treatment. However, further studies are needed to validate their diagnostic value in larger cohorts of patients and to integrate them into clinical practice. The development of multi-omics approaches that combine different types of biomarkers may provide a more comprehensive understanding of the disease pathogenesis and potential treatments.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75827641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kolsoum Teimouri, K. Khoshgard, M. Rouzbahani, Samaneh Pakravan
One of the most prevalent cancers in women is breast cancer, which is typically treated with radiation therapy (RT) which can lead to cardiovascular (CV) disease. The severity of these complications depends on the amount of radiation to the heart. In addition to hurting the cardiac tissue, RT also damages the blood vessels. Individuals with left breast cancer have a higher risk of developing CV disease as a result of RT than those with right breast cancer. Furthermore, women with risk factors for heart disease, such as diabetes, high cholesterol, smoking, and family history, are more likely to develop CV disease side effects from RT.
{"title":"Cardiac alterations following radiation therapy in individuals with breast cancer","authors":"Kolsoum Teimouri, K. Khoshgard, M. Rouzbahani, Samaneh Pakravan","doi":"10.34172/jre.2023.25066","DOIUrl":"https://doi.org/10.34172/jre.2023.25066","url":null,"abstract":"One of the most prevalent cancers in women is breast cancer, which is typically treated with radiation therapy (RT) which can lead to cardiovascular (CV) disease. The severity of these complications depends on the amount of radiation to the heart. In addition to hurting the cardiac tissue, RT also damages the blood vessels. Individuals with left breast cancer have a higher risk of developing CV disease as a result of RT than those with right breast cancer. Furthermore, women with risk factors for heart disease, such as diabetes, high cholesterol, smoking, and family history, are more likely to develop CV disease side effects from RT.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72696414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kamyar Shokraee, Seyed Mohammad Hashem Montazeri, Soroush Moradi, F. Razavi, A. Parsaei, M. Masoumi
Introduction: Fibromyalgia (FM) syndrome is a chronic musculoskeletal disorder with extensive symptoms. Its most characteristic manifestation is the presence of persistent and diffuse chronic pain. The prevalence of this disease is 1% to 6% in different studies. Its exact nature and manifestations are not fully known; hence the empirical diagnosis of doctors and the proposed diagnostic criteria may differ in diagnosis. Objectives: This study aims to investigate the prevalence of FM symptoms among rheumatology patients, identify components of symptom and laboratory markers, and determine the interrater agreement between clinician judgment and diagnostic criteria. Patients and Methods: During one year, all patients referred to the rheumatology clinic were selected by simple sampling and underwent medical history collecting and physical examination by a single experienced rheumatologist, and the clinician’s judgment on the diagnosis of FM in the patients was recorded. Also, the American College of Rheumatology (ACR) standard questionnaire was used to evaluate the diagnosis of FM. Results: Between May 2018 and May 2019, 1762 patients were recruited, of whom 1428 (81%) were female, and 334 (19%) were male, with a mean age of 48.4±13.4 years. According to the rheumatologist and ACR criteria, 620 (35.1%) and 491 (27.8%) were diagnosed with FM respectively. Analysis indicated a lower agreement between the two in patients with underlying rheumatologic conditions of a mechanical origin. Younger age in patients with FM (P<0.001). A higher prevalence of FM was found among women (P<0.001). There was a significant correlation between concomitant rheumatologic conditions and FM occurrence (P=0.0004). Symptoms were clustered into 10 components with the component including fatigue explaining 22.18% of the variance in the results. Laboratory markers were clustered into 5 components. Conclusion: Fibromyalgia is a widespread disease among women that is frequently comorbid with other rheumatologic conditions. Agreement between ACR criteria and rheumatologist judgment is acceptable but can be improved by examining the symptoms in clusters rather than individually.
{"title":"Fibromyalgia among patients presenting to a rheumatology clinic: prevalence and diagnosis","authors":"Kamyar Shokraee, Seyed Mohammad Hashem Montazeri, Soroush Moradi, F. Razavi, A. Parsaei, M. Masoumi","doi":"10.34172/jre.2023.25093","DOIUrl":"https://doi.org/10.34172/jre.2023.25093","url":null,"abstract":"Introduction: Fibromyalgia (FM) syndrome is a chronic musculoskeletal disorder with extensive symptoms. Its most characteristic manifestation is the presence of persistent and diffuse chronic pain. The prevalence of this disease is 1% to 6% in different studies. Its exact nature and manifestations are not fully known; hence the empirical diagnosis of doctors and the proposed diagnostic criteria may differ in diagnosis. Objectives: This study aims to investigate the prevalence of FM symptoms among rheumatology patients, identify components of symptom and laboratory markers, and determine the interrater agreement between clinician judgment and diagnostic criteria. Patients and Methods: During one year, all patients referred to the rheumatology clinic were selected by simple sampling and underwent medical history collecting and physical examination by a single experienced rheumatologist, and the clinician’s judgment on the diagnosis of FM in the patients was recorded. Also, the American College of Rheumatology (ACR) standard questionnaire was used to evaluate the diagnosis of FM. Results: Between May 2018 and May 2019, 1762 patients were recruited, of whom 1428 (81%) were female, and 334 (19%) were male, with a mean age of 48.4±13.4 years. According to the rheumatologist and ACR criteria, 620 (35.1%) and 491 (27.8%) were diagnosed with FM respectively. Analysis indicated a lower agreement between the two in patients with underlying rheumatologic conditions of a mechanical origin. Younger age in patients with FM (P<0.001). A higher prevalence of FM was found among women (P<0.001). There was a significant correlation between concomitant rheumatologic conditions and FM occurrence (P=0.0004). Symptoms were clustered into 10 components with the component including fatigue explaining 22.18% of the variance in the results. Laboratory markers were clustered into 5 components. Conclusion: Fibromyalgia is a widespread disease among women that is frequently comorbid with other rheumatologic conditions. Agreement between ACR criteria and rheumatologist judgment is acceptable but can be improved by examining the symptoms in clusters rather than individually.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80891861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Alivand, Hanieh Molaee, Mostafa Assarroudi, Amin Fatehi Moazam, Sara Dehghan, Soleyman Alivand
Fibroblast growth factor 23 (FGF23) is a hormone that plays a critical role in regulating mineral homeostasis in the body. Specifically, FGF23 acts on the kidneys to decrease the reabsorption of phosphate from the blood and into the urine. This process helps to reduce serum phosphate levels and maintain balance alongside other hormones such as PTH. The primary responsibility of FGF23 is to regulate the balance of phosphate in the body. It does this by acting on the kidney cells to decrease the reabsorption of phosphate from the blood and into the urine. This process allows the body to excrete excess phosphate to maintain normal serum phosphate levels in the blood. In addition to regulating phosphate levels, FGF23 also plays a role in the metabolism of vitamin D. FGF23 can increase the metabolism of vitamin D to an inactive form, reducing the amount of active vitamin D in the body. This reduction in active vitamin D levels leads to decreased intestinal absorption of dietary calcium and phosphate. Abnormal levels of FGF23 in the body have been associated with several health concerns, particularly in patients with chronic kidney disease. High levels of FGF23 have been linked to the development of bone loss, vascular calcification, and cardiovascular disease. Conversely, low levels of FGF23 have been associated with an increased risk of mortality and cardiovascular disease in patients with kidney disease.
{"title":"An overview of fibroblast growth factor 23 and its role in kidney function","authors":"N. Alivand, Hanieh Molaee, Mostafa Assarroudi, Amin Fatehi Moazam, Sara Dehghan, Soleyman Alivand","doi":"10.34172/jre.2023.25100","DOIUrl":"https://doi.org/10.34172/jre.2023.25100","url":null,"abstract":"Fibroblast growth factor 23 (FGF23) is a hormone that plays a critical role in regulating mineral homeostasis in the body. Specifically, FGF23 acts on the kidneys to decrease the reabsorption of phosphate from the blood and into the urine. This process helps to reduce serum phosphate levels and maintain balance alongside other hormones such as PTH. The primary responsibility of FGF23 is to regulate the balance of phosphate in the body. It does this by acting on the kidney cells to decrease the reabsorption of phosphate from the blood and into the urine. This process allows the body to excrete excess phosphate to maintain normal serum phosphate levels in the blood. In addition to regulating phosphate levels, FGF23 also plays a role in the metabolism of vitamin D. FGF23 can increase the metabolism of vitamin D to an inactive form, reducing the amount of active vitamin D in the body. This reduction in active vitamin D levels leads to decreased intestinal absorption of dietary calcium and phosphate. Abnormal levels of FGF23 in the body have been associated with several health concerns, particularly in patients with chronic kidney disease. High levels of FGF23 have been linked to the development of bone loss, vascular calcification, and cardiovascular disease. Conversely, low levels of FGF23 have been associated with an increased risk of mortality and cardiovascular disease in patients with kidney disease.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"69 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86897380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Asal Radmanesh, Setare Choromzade, E. Akade, Mohamad Bahadoram, G. Kaydani
Magnesium deficiency is a vital contributing factor to the happening and arising of insulin resistance, metabolic syndrome, and type 2 diabetes mellitus. Magnesium has a critical function in controlling the level of glucose in the blood and insulin sensitivity, acting as a cofactor for various enzymes such as enzymes involved in carbohydrate oxidation, glucose transport mechanisms of the cell membrane, cell replication, and lipid metabolism. Studies have indicated that reduced magnesium levels in the blood are connected with a significant decline in insulin-mediated glucose uptake which is a vital part of the cell’s metabolism. In people with type 2 diabetes, plasma magnesium concentration was inversely associated with markers of insulin resistance. This means as magnesium levels in plasma decrease, the risk of insulin resistance increases. Additionally, magnesium deficiency can play a role in the development of diabetes by affecting the activity of the Na/K-ATPase enzyme, pancreas inflammation, reactive oxygen species (ROS) modification, lipid metabolism, and causing genetic instability, as the main contributors to type 2 diabetes. Therefore, early detection of magnesium deficiency can help prevent further complications. Physicians should be aware of the connection between magnesium deficiency and diabetes and monitor patients with magnesium deficiency for diabetes symptoms and make sure that the patient is getting adequate amounts of magnesium from their diet. Further research is needed to reveal the exact mechanisms underlying magnesium deficiency-induced type 2 diabetes and the curative effects of magnesium supplementation.
镁缺乏是胰岛素抵抗、代谢综合征和2型糖尿病发生和发展的重要因素。镁在控制血液中葡萄糖水平和胰岛素敏感性方面具有关键作用，作为各种酶的辅助因子，如涉及碳水化合物氧化，细胞膜葡萄糖运输机制，细胞复制和脂质代谢的酶。研究表明，血液中镁含量的降低与胰岛素介导的葡萄糖摄取显著下降有关，而葡萄糖摄取是细胞代谢的重要组成部分。在2型糖尿病患者中，血浆镁浓度与胰岛素抵抗标志物呈负相关。这意味着随着血浆中镁含量的降低，胰岛素抵抗的风险增加。此外，缺镁可通过影响Na/ k - atp酶的活性、胰腺炎症、活性氧(ROS)修饰、脂质代谢和引起遗传不稳定，在糖尿病的发展中发挥作用，是2型糖尿病的主要诱因。因此，早期发现缺镁有助于预防进一步的并发症。医生应该意识到缺镁和糖尿病之间的联系，监测缺镁患者的糖尿病症状，并确保患者从饮食中摄取足量的镁。镁缺乏诱导2型糖尿病的确切机制和镁补充剂的疗效有待进一步研究。
{"title":"Magnesium deficiency as a contributing factor to type 2 diabetes: a review of the literature","authors":"Asal Radmanesh, Setare Choromzade, E. Akade, Mohamad Bahadoram, G. Kaydani","doi":"10.34172/jre.2023.25086","DOIUrl":"https://doi.org/10.34172/jre.2023.25086","url":null,"abstract":"Magnesium deficiency is a vital contributing factor to the happening and arising of insulin resistance, metabolic syndrome, and type 2 diabetes mellitus. Magnesium has a critical function in controlling the level of glucose in the blood and insulin sensitivity, acting as a cofactor for various enzymes such as enzymes involved in carbohydrate oxidation, glucose transport mechanisms of the cell membrane, cell replication, and lipid metabolism. Studies have indicated that reduced magnesium levels in the blood are connected with a significant decline in insulin-mediated glucose uptake which is a vital part of the cell’s metabolism. In people with type 2 diabetes, plasma magnesium concentration was inversely associated with markers of insulin resistance. This means as magnesium levels in plasma decrease, the risk of insulin resistance increases. Additionally, magnesium deficiency can play a role in the development of diabetes by affecting the activity of the Na/K-ATPase enzyme, pancreas inflammation, reactive oxygen species (ROS) modification, lipid metabolism, and causing genetic instability, as the main contributors to type 2 diabetes. Therefore, early detection of magnesium deficiency can help prevent further complications. Physicians should be aware of the connection between magnesium deficiency and diabetes and monitor patients with magnesium deficiency for diabetes symptoms and make sure that the patient is getting adequate amounts of magnesium from their diet. Further research is needed to reveal the exact mechanisms underlying magnesium deficiency-induced type 2 diabetes and the curative effects of magnesium supplementation.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79092990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Underlying kidney diseases and their progression cease the function of kidney and raise the need for regular maintenance dialysis. Furthermore, nutritional requirements and blood born viral infections affect their quality of life. Objectives: This study aims to investigate viral incidence, underlying kidney diseases, nutritional status; and hepatitis B virus (HBV) immunity status in hemodialysis (HD) patients. Patients and Methods: A total of 330 end-stage renal disease (ESRD) patients were assessed for human immunodeficiency virus (HIV), HBV, hepatitis C virus (HCV) viruses using Enzyme-linked immunosorbent assay (ELISA) assay. The underlying kidney diseases were confirmed by a physician. Eighty-two subjects with diabetic nephropathy are referred to dietitian for nutritional assessments and body mass index (BMI) measurement. Hepatitis B surface antibody (Anti-HBs) tests were done at two different times of year for 94 qualified subjects. Results: Out of 330 patients 82 (24.8%) had diabetic mellitus (DM), 5 (1.5%) myocardial infarction (MI), 3 (0.9%) systemic lupus erythematosus (SLE), 55 (16.7%) hypertensive nephrosclerosis (HN), 3 (0.9%) obstructive nephropathy, 5 (1.5%) autosomal dominant polycystic kidney disease (ADPKD), and 4 (1.2%) glomerulonephritis. 45 cases (13.6%) had DM and HTN simultaneously. Eleven percent of diabetic nephropathy (DN) patients had severe malnutrition. Only five men (1.51%) were positive for HBV. No incidence of HCV and HIV was seen. Findings showed a dramatic change for anti-HBs after 6 months. Conclusion: Despite the advances in medicine, malnutrition and viral diseases still threaten dialysis patients. DM was the most common underlying disease. The safety of dialysis patients for HBV is compromised after regular dialysis, underscoring the importance of strict adherence to vaccination program.
{"title":"Underlying diseases, nutritional assessment, viral incidence and HBV immunity status in patients undergoing hemodialysis","authors":"M. Musavi, A. Rasoolzadeh, M. Salehi, Hadi Fazel","doi":"10.34172/jre.2023.25085","DOIUrl":"https://doi.org/10.34172/jre.2023.25085","url":null,"abstract":"Introduction: Underlying kidney diseases and their progression cease the function of kidney and raise the need for regular maintenance dialysis. Furthermore, nutritional requirements and blood born viral infections affect their quality of life. Objectives: This study aims to investigate viral incidence, underlying kidney diseases, nutritional status; and hepatitis B virus (HBV) immunity status in hemodialysis (HD) patients. Patients and Methods: A total of 330 end-stage renal disease (ESRD) patients were assessed for human immunodeficiency virus (HIV), HBV, hepatitis C virus (HCV) viruses using Enzyme-linked immunosorbent assay (ELISA) assay. The underlying kidney diseases were confirmed by a physician. Eighty-two subjects with diabetic nephropathy are referred to dietitian for nutritional assessments and body mass index (BMI) measurement. Hepatitis B surface antibody (Anti-HBs) tests were done at two different times of year for 94 qualified subjects. Results: Out of 330 patients 82 (24.8%) had diabetic mellitus (DM), 5 (1.5%) myocardial infarction (MI), 3 (0.9%) systemic lupus erythematosus (SLE), 55 (16.7%) hypertensive nephrosclerosis (HN), 3 (0.9%) obstructive nephropathy, 5 (1.5%) autosomal dominant polycystic kidney disease (ADPKD), and 4 (1.2%) glomerulonephritis. 45 cases (13.6%) had DM and HTN simultaneously. Eleven percent of diabetic nephropathy (DN) patients had severe malnutrition. Only five men (1.51%) were positive for HBV. No incidence of HCV and HIV was seen. Findings showed a dramatic change for anti-HBs after 6 months. Conclusion: Despite the advances in medicine, malnutrition and viral diseases still threaten dialysis patients. DM was the most common underlying disease. The safety of dialysis patients for HBV is compromised after regular dialysis, underscoring the importance of strict adherence to vaccination program.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"2006 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78880443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ali Rastegar-Kashkouli, Mohsen Jafari, Pourya Yousefi, S. Alimohammadi, Hoda Miranzadeh Mahabadi, S. Toumaj, Zahra Taheri, Kamran Shirbache, Ali Shirbacheh, H. Mardanparvar, H. Nasri
Each year, a considerable number of individuals are diagnosed with potentially life-threatening renal failure, encompassing acute kidney injury (AKI) and chronic kidney disease (CKD). New natural herbal compounds, whether used in isolation or combined with medical treatments and an appropriate regime, have been suggested for the management of renal failure. The etiology of AKI remains uncertain; nevertheless, several factors have been proposed as potential causative agents that can lead to renal failure, including renal ischemia-reperfusion injury (IRI), nephrotoxicity, sepsis, administration of radiocontrast agents, and exposure to heavy metal ions. Several commonly utilized herbs with anti-diabetic and antihypertensive properties, known for their antioxidant, anti-inflammatory, and vasorelaxant effects, have been recognized as efficacious therapeutic agents in the management of CKD. The management of renal failure typically involves treating the underlying diseases, such as IRI, sepsis, and diabetes. However, if addressing the root cause is not possible, the focus shifts to managing complications like hypertension and proteinuria.
{"title":"Herbal medicine in the management of renal disease: A comprehensive review of its potential for acute kidney injury, chronic kidney disease, diabetic nephropathy, and hypertension","authors":"Ali Rastegar-Kashkouli, Mohsen Jafari, Pourya Yousefi, S. Alimohammadi, Hoda Miranzadeh Mahabadi, S. Toumaj, Zahra Taheri, Kamran Shirbache, Ali Shirbacheh, H. Mardanparvar, H. Nasri","doi":"10.34172/jre.2023.25092","DOIUrl":"https://doi.org/10.34172/jre.2023.25092","url":null,"abstract":"Each year, a considerable number of individuals are diagnosed with potentially life-threatening renal failure, encompassing acute kidney injury (AKI) and chronic kidney disease (CKD). New natural herbal compounds, whether used in isolation or combined with medical treatments and an appropriate regime, have been suggested for the management of renal failure. The etiology of AKI remains uncertain; nevertheless, several factors have been proposed as potential causative agents that can lead to renal failure, including renal ischemia-reperfusion injury (IRI), nephrotoxicity, sepsis, administration of radiocontrast agents, and exposure to heavy metal ions. Several commonly utilized herbs with anti-diabetic and antihypertensive properties, known for their antioxidant, anti-inflammatory, and vasorelaxant effects, have been recognized as efficacious therapeutic agents in the management of CKD. The management of renal failure typically involves treating the underlying diseases, such as IRI, sepsis, and diabetes. However, if addressing the root cause is not possible, the focus shifts to managing complications like hypertension and proteinuria.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78518994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Salehi, Najmeh Rayatpisheh, M. Salehi, H. Mardanparvar
Diabetes mellitus is a chronic condition suffering millions of people worldwide. According to the International Diabetes Federation (IDF), it is estimated that by 2045 about 783 million people will be affected by this disease. Diabetes can be treated today with various hypoglycemic drugs, including metformin and sulfonylureas. However, it has unwanted side effects, such as nausea, diarrhea, hypothyroidism, weight gain, liver failure, tachycardia, and lactic acidosis. A newer group of oral diabetes drugs, such as the sodium-glucose co-transporter inhibitors (SGLTi), are recognized as useful in treating blood sugar levels in diabetic patients. Natural phytochemicals derived from plants have long been used to treat chronic diseases such as diabetes, and traditional phytotherapy for diabetes has been recommended by the world health organization. Herbal medicines are believed to have fewer side effects, so nearly 80% of the drugs are derived directly from plants or modified plants. Given the importance of these results, we were inspired to investigate the impact of phytochemicals with his SGLT2 inhibitory effects on diabetes in order to develop the next generation of safer therapeutic strategies for diabetic patients.
{"title":"Phytochemicals with sodium-glucose co-transporter inhibitory effects for the management of diabetes; a narrative review on recent findings","authors":"M. Salehi, Najmeh Rayatpisheh, M. Salehi, H. Mardanparvar","doi":"10.34172/jre.2023.25095","DOIUrl":"https://doi.org/10.34172/jre.2023.25095","url":null,"abstract":"Diabetes mellitus is a chronic condition suffering millions of people worldwide. According to the International Diabetes Federation (IDF), it is estimated that by 2045 about 783 million people will be affected by this disease. Diabetes can be treated today with various hypoglycemic drugs, including metformin and sulfonylureas. However, it has unwanted side effects, such as nausea, diarrhea, hypothyroidism, weight gain, liver failure, tachycardia, and lactic acidosis. A newer group of oral diabetes drugs, such as the sodium-glucose co-transporter inhibitors (SGLTi), are recognized as useful in treating blood sugar levels in diabetic patients. Natural phytochemicals derived from plants have long been used to treat chronic diseases such as diabetes, and traditional phytotherapy for diabetes has been recommended by the world health organization. Herbal medicines are believed to have fewer side effects, so nearly 80% of the drugs are derived directly from plants or modified plants. Given the importance of these results, we were inspired to investigate the impact of phytochemicals with his SGLT2 inhibitory effects on diabetes in order to develop the next generation of safer therapeutic strategies for diabetic patients.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88982724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Nasri, Sepideh Ghanbari-nejad, M. Dehghani, A. Dieti
Implication
含义
{"title":"Sodium-glucose co-transporter-2 inhibitors in renal failure patients; expanding indications and prospective trends","authors":"H. Nasri, Sepideh Ghanbari-nejad, M. Dehghani, A. Dieti","doi":"10.34172/jre.2023.25084","DOIUrl":"https://doi.org/10.34172/jre.2023.25084","url":null,"abstract":"Implication","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"126 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87710922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：